Welcome to our dedicated page for Dariohealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DarioHealth Corp. filings document the regulatory record of a Nasdaq-listed digital health company with common stock registered under the Exchange Act. Recent 8-K reports cover material agreements, including equity offering arrangements, securities purchase agreements and amendments to credit facilities, along with related capital-structure disclosures involving common stock, preferred stock and pre-funded warrants.
The company’s filings also record governance and charter matters, including amendments to its certificate of incorporation, preferred stock designation changes, annual meeting voting results and board appointments. These disclosures frame DRIO’s formal reporting around financing activity, security-holder rights, corporate governance and material events tied to its digital therapeutics business.
DarioHealth Corp. (DRIO) director Yoav Shaked reported a restricted share award granted and recorded on 09/11/2025. The filing shows an acquisition of 20,000 shares of common stock at a reported price of $0, structured to vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period. After accounting for a 20-for-1 reverse stock split effected on August 28, 2025, the number of shares beneficially owned by Mr. Shaked is shown as 32,810.
The report also discloses indirect ownership of 84 shares held by the reporting person’s spouse, with the reporting person disclaiming beneficial ownership of those shares. The form is signed by Yoav Shaked on 09/15/2025.
Raphael Erez, who is listed as Chief Executive Officer and a director of DarioHealth Corp. (DRIO), reported a non‑derivative award on this Form 4. On 09/11/2025 he was granted 60,000 restricted shares at a stated price of $0; the award vests in two equal installments on the last day of each successive annual anniversary over a two‑year period. Following the grant and reflecting a 20‑for‑1 reverse stock split effected August 28, 2025, the filing reports total beneficial ownership of 156,853 common shares. The filing also discloses indirect ownership of 1,894 shares through Dicilyon Consulting and Investment Ltd. The report is signed by Mr. Erez on 09/15/2025.
DarioHealth Corp. insider transaction summary The reporting person, Dennis M. McGrath, a company director, received a restricted share award of 20,000 shares of DarioHealth common stock on 09/11/2025 that vests on the last day of the second anniversary of the grant date. Following the award and a prior corporate action, Mr. McGrath is shown as beneficially owning 27,737 shares, an amount that reflects a 20-for-1 reverse stock split effected on 08/28/2025. The transaction is recorded as an acquisition with a reported price of $0 for the restricted shares.
DarioHealth Corp. director Dennis Matheis reported a non‑derivative acquisition of company stock. On 09/11/2025 Mr. Matheis received a restricted share award of 20,000 shares at a reported price of $0. The award is scheduled to vest on the last day of the second anniversary after the grant date. Following the reported transaction, Mr. Matheis beneficially owned 27,631 shares, an amount that reflects a 20‑for‑1 reverse stock split effected on August 28, 2025. The Form 4 was signed on 09/15/2025.
Steven Nelson, President and CCO of DarioHealth Corp. (DRIO), reported an open-market purchase of common stock on 08/27/2025. The Form 4 shows a purchase of 40,000 shares at $0.53 per share, bringing his reported beneficial ownership to 95,000 shares. The filing identifies Nelson as a director and officer and is signed by him on 08/27/2025.
DarioHealth Corp. filed an 8-K dated August 25, 2025 disclosing a Certificate of Amendment to its Certificate of Incorporation to implement a reverse stock split. The filing lists a press release dated August 25, 2025 and confirms submission of an interactive XBRL cover page. The document names the company's registered common stock (par value $0.0001) and the trading symbol DRIO on The Nasdaq Capital Market LLC, and is signed by the Chief Financial Officer, Treasurer and Secretary, Chen Franco-Yehuda.
DarioHealth Corp. reporting persons Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack disclose beneficial ownership of 4,690,019 shares, representing 9.99% of the outstanding common stock as of June 30, 2025. The disclosed position includes 2,997,716 shares that may be acquired within 60 days through the exercise of warrants, and all voting and dispositive power is reported as shared rather than sole. Nantahala identifies two advised funds with rights to receive proceeds or dividends from more than 5% of the shares reported.
DarioHealth Corp. reported total revenues of $5.369 million for the quarter ended June 30, 2025, split between Services $3.661M and Consumer hardware $1.708M. Gross profit was $2.964M for the quarter and $6.846M for the six months, while operating expenses were $12.164M for the quarter, producing an operating loss of $9.200M. The company recorded a net loss of $12.990M for the quarter and $22.217M for the six months; basic and diluted loss per share was $0.18 for the quarter and $0.33 for six months.
On the balance sheet, cash and cash equivalents were $21.954M (down from $27.764M at year-end), total assets were $108.325M, and accumulated deficit totaled $422.971M. The company refinanced with a $32.5M Callodine credit agreement on April 30, 2025, but did not meet one covenant as of June 30, 2025; Callodine waived the default conditional on a successful equity cure by November 15, 2025. Management discloses that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from issuance.